Antibody response to aerosolized transgenic human alpha1- antitrypsin [6]

New England Journal of Medicine

Volumn 352, Issue 19, 2005, Pages 2030-2032

  Spencer, L Terry ^a   Humphries, John E ^b   Brantly, Mark L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; BETA LACTOGLOBULIN; COMPLEMENTARY DNA; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY RESPONSE; COUGHING; DRUG ISOLATION; DRUG SAFETY; DYSPNEA; EMPHYSEMA; HUMAN; HYPOXEMIA; IMMUNOGENICITY; LETTER; LUNG DISEASE; LUNG FUNCTION; LUNG INFILTRATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RISK ASSESSMENT; SAFETY; SIDE EFFECT; TRANSGENICS;

AEROSOLS; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; ANIMALS, GENETICALLY MODIFIED; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOGLOBULIN G; SHEEP; TRANSGENES;

EID: 18344379191     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200505123521923     Document Type: Letter

References (3)

1. Nightingale SD. Summary of the Advisory Committee on Blood Safety and Availability Meeting on April 27 and 28, 1998. Washington, D.C.; Department of Health and Human Services, 1998. (Accessed April 21, 2005, at http://www.hhs.gov/bloodsafety/summaries/sumapr98.html.)
2. Wright G, Carver A, Cottom D, et al. High level expression of active human alpha-1-antittypsin in the milk of transgenic sheep. Biotechnology (N.Y.) 1991;9:830-4.
3. Blank CA, Brantly M. Clinical features and molecular characteristics of alpha 1-antittypsin deficiency. Ann Allergy 1994;72:105-20. [Erratum, Ann Allergy 1994;72:305.]